{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:15:46Z","timestamp":1789402546620,"version":"build-2803163510"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":775,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22ek0210149"],"award-info":[{"award-number":["JP22ek0210149"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22ek0210149"],"award-info":[{"award-number":["JP22ek0210149"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The pathophysiology of pulmonary hypertension (PH) due to left-sided heart disease (Group 2 PH) is distinct from that of other groups of PH, yet there are still no approved therapies that selectively target pulmonary circulation. The increase in pulmonary capillary pressure due to left-sided heart disease is a trigger event for physical and biological alterations of the pulmonary circulation, including the nitric oxide (NO)\u2013soluble guanylate cyclase\u2013cyclic guanosine monophosphate axis. This study investigated inhaled NO vasoreactivity tests for patients with Group 2 PH and hypothesized that these changes may have a prognostic impact.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This was a single-centre, retrospective study with a median follow-up of 365 days. From January 2011 to December 2015, we studied 69 patients with Group 2 PH [age, 61.5 \u00b1 13.0 (standard deviation) years; male:female, 49:20; left ventricular ejection fraction, 50.1 \u00b1 20.4%; mean pulmonary arterial pressure, \u226525 mmHg; and pulmonary arterial wedge pressure (PAWP), &amp;gt;15 mmHg]. No adverse events were observed after NO inhalation. Thirty-four patients with Group 2 PH showed increased PAWP (\u0394PAWP: 3.26 \u00b1 2.22 mmHg), while the remaining 35 patients did not (\u0394PAWP: \u22122.11 \u00b1 2.29 mmHg). Multivariate analysis revealed that increased PAWP was the only significant predictor of all-cause death or hospitalization for heart failure (HF) after 1 year (hazard ratio 4.35; 95% confidence interval, 1.27\u201314.83; P = 0.019). The acute response of PAWP to NO differed between HF with preserved and reduced ejection fractions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with Group 2 PH were tolerant of the inhaled NO test. NO-induced PAWP is a novel prognostic indicator.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14515","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T01:39:51Z","timestamp":1696037991000},"page":"3592-3603","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Inhaled Nitric Oxide Testing in Predicting Prognosis in Pulmonary Hypertension Due to Left-Sided Heart Diseases"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1795-6872","authenticated-orcid":false,"given":"Taijyu","family":"Satoh","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine , Sendai ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Yaoita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine , Sendai ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Nochioka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine , Sendai ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Tatebe","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine , Sendai ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideka","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine , Sendai ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine , Sendai ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine , Sendai ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takahama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine , Sendai ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine , Sendai ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Terui","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine , Sendai ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaito","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine , Sendai ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine , Sendai ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine , Sendai ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Advanced Medicine in Pulmonary Hypertension, National Cerebral and Cardiovascular Center , Suita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimio","family":"Satoh","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine , Sendai ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Sugimura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, International University of Health and Welfare , Otawara ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Miyata","sequence":"additional","affiliation":[{"name":"Teikyo University Graduate School of Public Health , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine , Sendai ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,29]]},"reference":[{"key":"2026012113205036500_ehf214515-bib-0001","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"2026012113205036500_ehf214515-bib-0002","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01897-2018","article-title":"Pulmonary hypertension due to left heart disease","volume":"53","author":"Vachiery","year":"2019","journal-title":"Eur Respir J"},{"key":"2026012113205036500_ehf214515-bib-0003","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1152\/physrev.00036.2017","article-title":"Sources of vascular nitric oxide and reactive oxygen species and their regulation","volume":"99","author":"Tejero","year":"2019","journal-title":"Physiol Rev"},{"key":"2026012113205036500_ehf214515-bib-0004","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/CRD.0b013e3181c8e14a","article-title":"Nitrates and nitrites in the treatment of ischemic cardiac disease","volume":"18","author":"Nossaman","year":"2010","journal-title":"Cardiol Rev"},{"key":"2026012113205036500_ehf214515-bib-0005","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S2213-2600(20)30532-4","article-title":"Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): A multicentre, open-label, randomised controlled trial","volume":"9","author":"Hoeper","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026012113205036500_ehf214515-bib-0006","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012113205036500_ehf214515-bib-0007","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED randomized trial","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"key":"2026012113205036500_ehf214515-bib-0008","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: The VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"2026012113205036500_ehf214515-bib-0009","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","article-title":"Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: A phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study","volume":"128","author":"Bonderman","year":"2013","journal-title":"Circulation"},{"key":"2026012113205036500_ehf214515-bib-0010","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"37","author":"Galie","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012113205036500_ehf214515-bib-0011","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.pcad.2015.09.006","article-title":"Role of vasodilator testing in pulmonary hypertension","volume":"58","author":"Sharma","year":"2016","journal-title":"Prog Cardiovasc Dis"},{"key":"2026012113205036500_ehf214515-bib-0012","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.883911","article-title":"Pulmonary vasculature responsiveness to phosphodiesterase-5A inhibition in heart failure with reduced ejection fraction: Possible role of plasma potassium","volume":"9","author":"Monzo","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026012113205036500_ehf214515-bib-0013","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1253\/circj.CJ-16-0799","article-title":"Age-specific trends in the incidence and in-hospital mortality of acute myocardial infarction over 30 years in Japan\u2014Report from the Miyagi AMI Registry Study","volume":"81","author":"Cui","year":"2017","journal-title":"Circ J"},{"key":"2026012113205036500_ehf214515-bib-0014","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1002\/ehf2.13941","article-title":"Prognostic impact of a history of cancer and atrial fibrillation in antithrombotic therapy for chronic heart failure","volume":"9","author":"Nochioka","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026012113205036500_ehf214515-bib-0015","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamacardio.2018.0128","article-title":"Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction","volume":"3","author":"Vanderpool","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026012113205036500_ehf214515-bib-0016","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jchf.2014.04.008","article-title":"Risk prediction in patients with heart failure: A systematic review and analysis","volume":"2","author":"Rahimi","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026012113205036500_ehf214515-bib-0017","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1365-2125.2012.04420.x","article-title":"Vascular effects of dietary nitrate (as found in green leafy vegetables and beetroot) via the nitrate-nitrite-nitric oxide pathway","volume":"75","author":"Lidder","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"2026012113205036500_ehf214515-bib-0018","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1086\/680355","article-title":"Sildenafil versus nitric oxide for acute vasodilator testing in pulmonary arterial hypertension","volume":"5","author":"Milger","year":"2015","journal-title":"Pulm Circ"},{"key":"2026012113205036500_ehf214515-bib-0019","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11123507","article-title":"The analysis of arterial stiffness in heart failure patients: The prognostic role of pulse wave velocity, augmentation index and stiffness index","volume":"11","author":"Anastasio","year":"2022","journal-title":"J Clin Med"},{"key":"2026012113205036500_ehf214515-bib-0020","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00380-018-1150-4","article-title":"Comparable prognostic impact of BNP levels among HFpEF, Borderline HFpEF and HFrEF: A report from the CHART-2 Study","volume":"33","author":"Kasahara","year":"2018","journal-title":"Heart Vessels"},{"key":"2026012113205036500_ehf214515-bib-0021","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1161\/01.CIR.90.6.2780","article-title":"Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction","volume":"90","author":"Loh","year":"1994","journal-title":"Circulation"},{"key":"2026012113205036500_ehf214515-bib-0022","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/0735-1097(94)90859-1","article-title":"Hemodynamic effects of inhaled nitric oxide in heart failure","volume":"24","author":"Semigran","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"2026012113205036500_ehf214515-bib-0023","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.healun.2012.06.002","article-title":"World Health Organization Pulmonary Hypertension group 2: Pulmonary hypertension due to left heart disease in the adult\u2014A summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation","volume":"31","author":"Fang","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"2026012113205036500_ehf214515-bib-0024","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ijcard.2019.11.139","article-title":"Current status of long-term prognosis among all subtypes of pulmonary hypertension in Japan","volume":"300","author":"Kozu","year":"2020","journal-title":"Int J Cardiol"},{"key":"2026012113205036500_ehf214515-bib-0025","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1253\/circj.CJ-66-0158","article-title":"Guidelines for the treatment of pulmonary hypertension (JCS 2017\/JPCPHS 2017)","volume":"83","author":"Fukuda","year":"2019","journal-title":"Circ J"},{"key":"2026012113205036500_ehf214515-bib-0026","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012113205036500_ehf214515-bib-0027","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: Results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/6\/3592\/64699420\/eschf_10_6_3592.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/6\/3592\/64699420\/eschf_10_6_3592.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:25:15Z","timestamp":1769019915000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/6\/3592\/8284362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,9,29]]},"published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14515","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,9,29]]},"assertion":[{"value":"2023-05-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}